Bevacizumab in high-grade gliomas: past, present, and future.

Richard C Curry; Saurabh Dahiya; Vyshak Alva Venur; Jeffrey J Raizer; Manmeet S Ahluwalia

doi:10.1586/14737140.2015.1028376

Bevacizumab in high-grade gliomas: past, present, and future.

Richard C Curry
, Saurabh Dahiya
, Vyshak Alva Venur
, Jeffrey J Raizer
, Manmeet S Ahluwalia

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Expert Review of Anticancer Therapy
Volume	15
DOIs	https://doi.org/10.1586/14737140.2015.1028376
State	Published - Mar 21 2015

Disciplines

Medicine and Health Sciences
Oncology
Pathology

Access to Document

10.1586/14737140.2015.1028376License: Unspecified

Cite this

@article{2a751d7df3814b47bf17e2d5bfdc5fd3,

title = "Bevacizumab in high-grade gliomas: past, present, and future.",

author = "Curry, \{Richard C\} and Saurabh Dahiya and Venur, \{Vyshak Alva\} and Raizer, \{Jeffrey J\} and Ahluwalia, \{Manmeet S\}",

note = "The survival of patients with high-grade gliomas (anaplastic gliomas and glioblastoma) remains poor despite current treatment modalities. However, an enhanced understanding of gliomagenesis is supporting the development of targeted molecular therapies with the potential for improving clinical outcomes. Glioblastoma (GBM) is characterized by extensive microvascular proliferation and the production of large amounts of VEGF.",

year = "2015",

month = mar,

day = "21",

doi = "10.1586/14737140.2015.1028376",

language = "American English",

volume = "15",

journal = "Expert Review of Anticancer Therapy",

}

TY - JOUR

T1 - Bevacizumab in high-grade gliomas: past, present, and future.

AU - Curry, Richard C

AU - Dahiya, Saurabh

AU - Venur, Vyshak Alva

AU - Raizer, Jeffrey J

AU - Ahluwalia, Manmeet S

N1 - The survival of patients with high-grade gliomas (anaplastic gliomas and glioblastoma) remains poor despite current treatment modalities. However, an enhanced understanding of gliomagenesis is supporting the development of targeted molecular therapies with the potential for improving clinical outcomes. Glioblastoma (GBM) is characterized by extensive microvascular proliferation and the production of large amounts of VEGF.

PY - 2015/3/21

Y1 - 2015/3/21

UR - https://scholarlycommons.libraryinfo.bhs.org/all_works/7981/

U2 - 10.1586/14737140.2015.1028376

DO - 10.1586/14737140.2015.1028376

M3 - Article

VL - 15

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

ER -

Bevacizumab in high-grade gliomas: past, present, and future.

Disciplines

Access to Document

Other files and links

Cite this